London UK:
On Monday 10th December, The Academy of Medical Sciences in London played host to the invitation only ‘Blueprint launch event’ hosted by CMC (Centre For Medicinal Cannabis) A select group of delegates attended. Amongst the invitees was Dr Callie Seaman, a director of Hempire Limited.
Founded in 2018, the CMC is a non-profit organisation consisting of philanthropists, scientists, campaigners, public policy experts and educators who aim to advance responsible, ethical and evidence based access to medicinal cannabis. Led by Steve Moore from Volteface, CMC are working to shape the UK’s new medicinal cannabis regime in the interests of patients by engaging with engage with UK regulators and all relevant public authorities.
The day started with an introduction by Steve Moore, the day seen the launch and publication of Blueprint which is a credible and compelling model for the UK’s medical cannabis regime. Blueprint is evidence based and politically deliverable
It’s clear that when dealing with a plant that has been scheduled for so many years that a lack of knowledge persists. Policy makers need to understand the science behind medicinal cannabis such as the entourage effect and CMC aim to be key in this learning process by bringing together those who have experience in all aspects from seed genetics to medical data from around the world.
